| Title | Date Published | Source |
|---|---|---|
| Update on FDA Safety Review of Bisphosphonates | 2008-Nov-13 | FDA |
| Use of alendronate (Fosamax) by women associated with an increased risk of an abnormal heart rhythm | 2008-Aug-13 | iGuard CRT |
| New Consumer Guide for Patients | 2008-Jul-03 | iGuard CRT |
| FDA Communication Regarding Musculoskeletal Pain | 2008-Jan-07 | FDA |
| Early communication of ongoing safety review | 2007-Oct-01 | FDA |
DISCLAIMER: iGuard is not intended to be a substitute for professional medical advice. iGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the iGuard site and its content is at your own risk. The iGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.
